An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome
Latest Information Update: 04 Jun 2024
At a glance
- Drugs Trofinetide (Primary)
- Indications Rett syndrome
- Focus Adverse reactions; Pharmacokinetics
- Acronyms DAFFODIL
- Sponsors Acadia Pharmaceuticals
- 18 Apr 2024 Final results assessing the safety tolerability and exploratory efficacy of long-term treatment with trofinetide in girls aged 2-4 years with Rett syndrome presented at the 76th Annual Meeting of the American Academy of Neurology 2024
- 17 Apr 2024 According to an Acadia Pharmaceuticals media release, data from the study will be presented at the American Academy of Neurology (AAN) 2024 annual meeting, being held this week in Denver, CO.
- 12 Sep 2023 Results assessing Population Pharmacokinetic Modelling to Predict Trofnetide Exposure & Exposure-Response Safety Analyses in Girls With Rett Syndrome Aged 2-4 Years presented at the 2023 American College of Clinical Pharmacology Annual Meeting